Security observation of intraperitoneal perfusion chemotherapy with Raltitrexed in laparoscopic radical operation for colorectal cancer

doi:10.12092/j.issn.1009-2501.2018.03.012

Abstract

Abstract:

AIM: To observe and evaluate the postoperative complication and adverse reaction, postoperative recovery and systemic toxicity of intraperitoneal perfusion chemotherapy with raltitrexed in laparoscopic radical operation for colorectal cancer. METHODS: The clinical data of 81 patients with colorectal cancer were analyzed. Group A underwent laparoscopic radical operation+intraperitoneal perfusion with Raltitrexed; Group B just underwent laparoscopic radical operation. General information, operative time, postoperative complication and adverse reaction, the recovery time of the bowel function, routine blood tests as well as liver and kidney functions before and 3 days after operation between the two groups were evaluated and compared. RESULTS: No statistically significant difference were observed with general information (P>0.05). No statistically significant difference were observed with postoperative complication and adverse reaction, the recovery time of the bowel function and operative time (P>0.05); No statistically significant difference were observed with WBC, PLT, AST, ALT, Cr and BUN before and 3 days after operation (P>0.05). CONCLUSION: Intraperitoneal perfusion chemotherapy with Raltitrexed in laparoscopic radical operation for colorectal cancer is safe and well tolerated to patient.

Key words: colorectal cancer, raltitrexed, laparoscopic radical operation, intraperitoneal perfusion

CLC Number:

R735.3

ZHANG Yang, CHEN Zhikang, GUO Xiong, WANG Wen. Security observation of intraperitoneal perfusion chemotherapy with Raltitrexed in laparoscopic radical operation for colorectal cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 313-318.

References

［1］Zhong YB, Qiu L, Xie PB, et al. Laparoscopic colorectal cancerresection in combination with intraoperative intraperitoneal hyperthermic perfusion chemotherapy［J］. Chin J General Surg, 2015, 24(4): 467-472.
［2］Votanopoulos KI, Swett K, Blackham AU, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer［J］. Ann Surg Oncol, 2013, 20(4): 1088-1092.
［3］Teo MC, Ching Tan GH, Lim C, et al. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center［J］. Asian J Surg, 2015, 38(2): 65-73.
［4］陈伟荣, 李平, 李社方, 等. CD44、NGAL、MIC-1在结直肠癌诊断及远期预后中的应用价值［J］. 疑难病杂志，2017, 16(5): 485-488.
［5］杨东，海栗斌，王钊. 进展期结直肠癌腹腔镜术中5-Fu腹腔冲洗联合缓释置入对手术近远期结局影响的研究［J］. 重庆医学, 2017, 4(46): 1684-1686.
［6］郭锰. 进展期胃癌术后腹腔化疗的临床疗效分析［J］. 中华肿瘤防治杂志, 2011, 5: 374-376.
［7］Nagao S, Kurosaki A, Iwasa N, et al. Intraperitoneal chemotherapy［J］. Nihon Rinsho, 2012, 70 Suppl 4: 610-616.
［8］Papparella A, Nino F, Coppola S, et al. Peritoneal morphological changes due to pneumoperitoneum: the effect of intra-abdominal pressure［J］. Eur J Pediatr Surg, 2014，24(4): 322-327.
［9］Obata S, Goi T, Nakazawa T, et al. Changes in CO2 concentration increase the invasive ability of colon cancer cells［J］. Anti-cancer Res, 2013, 33(5): 1881-1885.
［10］胡林，李昌荣，李红浪. 腹腔镜手术中超声气雾与肿瘤种植转移相关性研究进展［J］.中国实用外科杂志, 2014, 34(4): 372-375.
［11］王斌斌, 刘彩刚, 阿拉腾宝力德, 等. 淋巴结阴性进展期胃癌复发的模式和影响因素的回顾性研究［J］. 中华临床医师杂志, 2010, 4(12): 2526-2529.
［12］徐建军，刘殿明. 雷替曲塞以腹腔/静脉给药途径治疗结直肠癌腹水的疗效比较［J］. 东南国防医药, 2015, 17(1): 38-39.
［13］Martin S. Treatment of pancreatic exocrine deficiency［J］. World J Surg, 2003, 27(11): 1192-1195．
［14］Kunisaki C, Shimada H, Akiyama H, et al. Therapeutic outcomes of continuous hyperthermic peritoneal perfusion against advanced gastric cancer with peritoneal carcinomatosis［J］. Hepatogastroenterology, 2006, 53(69): 473-478.
［15］Kim JY, HS Bae. A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP)［J］. Gastric Cancer, 2001, 4(1): 27-33.
［16］Yonemura Y, AX De, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study［J］. Hepatogastroenterol, 2001, 48: 1776-1782.
［17］Panteix G, Beaujard A, Garbit F, et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy［J］. Anticancer Res, 2002, 22(2): 1329-1336.
［18］Seymour MT, Trigonis L, Finan PJ, et al. A feasibility, pharmacoki-netic and frequency-escalation trial of intraperitoneal chemotherapyin high risk gastrointestinal tract cancer［J］. EJSO, 2008, 34 (4): 403-409.
［19］Xu DZ, Zhao K, Guo LM, et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients［J］. PLoS One, 2008, 3(7):e2565.
［20］Laumbacher B, Gu S, Wank R. Prolongation of life by adoptive cell therapy with cascade primed immune cells in four patients with nonsmall cell lung cancer stages IIIB and IV and a pancoast tumor: a case series［J］. J Med Case Rep, 2013, 7(1): 266.
［21］Sugarbaker PH, Mora JT, Carmignani P, et al. Update on chemotherapeutic agents utilized for perioperative intraperitonaeal chemotherapy［J］. Oncologist, 2005, 10: 112-122.
［22］Tsavaris N, Kosmas C, Vadiaka M, et al. Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study［J］. Invest New Drugs, 2002, 20(1): 133-136.
［23］Barni S, Ghidini A, Coinu A, et al. A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer［J］. Anti Cancer Drugs, 2014, 25(10): 1122-1128.
［24］张月馨, 常靓, 刘巍. 抗癌药雷替曲塞的研究进展［J］. 临床荟萃, 2011, 21: 1928-1931.
［25］Comandone A, Oliva C, Dal Canton O, et al.［Raltitrexed in colorectal cancer］［J］. Tumori, 2001, 87(1 Suppl 1): S53-54.
［26］Sato KT, Lewandowski RJ, Mulcahy MF, et al.Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival［J］. Radiology, 2008, 247: 507-515.
［27］李如标, 张为民, 高英. 注射用雷替曲塞在晚期实体瘤患者体内的药动学［J］. 中国新药与临床杂志, 2011, 9: 709-712.
［28］臧金林, 周东风. 直肠癌 Dixon 术中应用雷替曲塞的安全性评估［J］. 中国现代普通外科进展, 2016, 19(12): 960-962.
［29］Zhao P, Ding Z. Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer［J］. World J Surg Oncol, 2014, 12(1): 1-7.

[1]	SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
[2]	WEI Zhenzhen, SUI Hua, JIANG Yulang, SUN Mingyu, YAN Huaru, WANG Ziyuan. Research on the molecular mechanism of Zuo Jin Wan combined with cetuximab inducing ferroptosis in KRAS mutant colorectal cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 130-137.
[3]	ZHOU Guangchen, LIU Yixi, ZHENG Yun. Colorectal cancer and microRNA: research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
[4]	LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui. circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.
[5]	LU Qiong, ZHU Haihong, QI Tingting, LI Guohua, TENG Xinqi, QU Qiang, QU Jian. OCTN2 gene polymorphisms affect the chemotherapeutic sensitivity of oxaliplatin in colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 401-407.
[6]	ZHANG Dezhi, LIU Meng, ZHU Shaogong, LIU Guiju, JI Jie. Efficacy and safety of XELOX therapy in comparison with capecitabine monotherapy in adjuvant chemotherapy for elderly patients with colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 926-936.
[7]	WANG Ziyuan, SUN Mingyu. Advances in research on long non-coding RNA in drug resistance of colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 796-802.
[8]	SHI Lili, LIU Xingan, SHAN Guoyong. Efficacy and safety of apatinib in the further line treatment for patients with advanced colorectal cancer failed after standard therapy and the preliminary analysis of efficacy predictors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1388-1394.
[9]	LI Rongzhen, MEI Jiazhuan, XIA Yunzhan, JI Jie. Prognostic factors and safety study of R0 resection colorectal cancer patients received capecitabine based adjuvant chemotherapy in real world [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 704-711.
[10]	QIAO Dawei, LI Yufang, XIAO Yun, JIANG Lishuang, BO Ping. Research progress of Scutellaria barbata against colorectal cancer and its metastasis mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 332-336.
[11]	BAI Yan, ZHENG Xiaoyong, YANG Yage, FANG Lifeng. Influence of programmed death-ligand 1 genetic variation on the clinical outcomes of postoperative CRC patients received 5-FU based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 180-187.
[12]	LI Xiaojie,ZHANG Shengwei,WANG Huasheng,WANG Dong, MEI Jiazhuan, DENG Yewei. Effects of polymorphism of vascular endothelial growth factor A on the prognosis of colorectal cancer patients received fluorouracil based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 900-904.
[13]	HU Yang, LI Zhixing, WANG Guo, ZHU Yuanshan. Research progress of lncRNA and chemotherapy resistance in colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 456-463.
[14]	XIAO Peng, MEI Jiazhuan, BAI Hua, LI Min, LIU Guiju, LI Ruijun, SHEN Jie. Influence of CYP1A1 polymorphism on clinical outcomes of CRC patients treated by oxaliplatin plus capecitabine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 159-164.
[15]	MAO Jiading, HU Di, WU Pei. Effects of gastrin on ERK signaling pathway in the proliferation of colorectal cancer cell line CACO2 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 401-405.